Effect of very early intervention with metoprolol on myocardial infarct size.

AUTOR(ES)

Boyle, D M

RESUMO

All patients with a presumptive diagnosis of myocardial infarction, who were seen within six hours of the onset of symptoms and had no reason for exclusion, were considered for entry into a trial to compare the effects of metoprolol and placebo on creatine kinase MB isoenzyme release. The trial was randomised and double blind. The median time from onset of symptoms to receiving trial drug was just under two hours. Two hundred and four patients (of whom 120 had myocardial infarction) received metoprolol and 187 (of whom 105 had myocardial infarction) received placebo. Infarct size was estimated semiquantitatively using cumulative release of the cardiospecific isoenzyme, creatine kinase MB. Mean creatine kinase MB isoenzyme was less in patients who received metoprolol, but the reduction did not achieve statistical significance. Clinical problems related to early intravenous metoprolol were uncommon.

Documentos Relacionados

• Comparison of enzymic with cineangiocardiographic estimations of myocardial infarct size.
• Limitation of enzymatic models for predicting myocardial infarct size.
• Effect of nifedipine on enzymatically estimated infarct size in the early phase of acute myocardial infarction.
• Improved detection of myocardial infarction by emission computed tomography with thallium-201. Relation to infarct size.
• Advantages of technetium pyrophosphate scintigraphy over plasma enzyme analysis in estimation of anterior myocardial infarct size.